Mirodenafil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mirodenafil
Accession Number
DB11792
Description

Mirodenafil has been used in trials studying the treatment and supportive care of Kidney Diseases, Urologic Diseases, Renal Insufficiency, Erectile Dysfunction, and Male Erectile Dysfunction.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 531.67
Monoisotopic: 531.251540485
Chemical Formula
C26H37N5O5S
Synonyms
Not Available
External IDs
  • SK-3530
  • SK3530

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololMirodenafil may increase the antihypertensive activities of Acebutolol.
AldesleukinThe risk or severity of hypotension can be increased when Mirodenafil is combined with Aldesleukin.
AlfuzosinThe risk or severity of hypotension, dyspepsia, and headache can be increased when Mirodenafil is combined with Alfuzosin.
AliskirenMirodenafil may increase the antihypertensive activities of Aliskiren.
AlprostadilThe risk or severity of hypotension and priapism can be increased when Mirodenafil is combined with Alprostadil.
AmbrisentanMirodenafil may increase the antihypertensive activities of Ambrisentan.
AmifostineThe risk or severity of hypotension can be increased when Mirodenafil is combined with Amifostine.
AmilorideThe risk or severity of hypotension can be increased when Mirodenafil is combined with Amiloride.
AmiodaroneThe risk or severity of hypotension can be increased when Mirodenafil is combined with Amiodarone.
AmitriptylineThe risk or severity of hypotension, dyspepsia, and headache can be increased when Mirodenafil is combined with Amitriptyline.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Pyrrolopyrimidines / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / N-alkylpiperazines / Pyrimidones / Organosulfonamides / Substituted pyrroles / Sulfonyls
show 9 more
Substituents
1,2-aminoalcohol / 1,4-diazinane / Alcohol / Alkanolamine / Alkyl aryl ether / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenesulfonamide / Benzenesulfonyl group
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
504G362H0H
CAS number
862189-95-5
InChI Key
MIJFNYMSCFYZNY-UHFFFAOYSA-N
InChI
InChI=1S/C26H37N5O5S/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33)
IUPAC Name
5-ethyl-2-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl}-2-propoxyphenyl)-7-propyl-3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one
SMILES
CCCOC1=CC=C(C=C1C1=NC2=C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1

References

General References
Not Available
PubChem Compound
12001014
PubChem Substance
347828141
ChemSpider
10173481
ZINC
ZINC000035077050
Wikipedia
Mirodenafil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentErectile Dysfunction2
2TerminatedTreatmentErectile Dysfunction1
1CompletedSupportive CareImpaired kidney function / Kidney Diseases / Urologic Diseases1
1CompletedTreatmentDrug Interaction Potentiation2
1CompletedTreatmentErectile Dysfunction3
Not AvailableTerminatedNot AvailableErectile Dysfunction1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.181 mg/mLALOGPS
logP2.85ALOGPS
logP2.44ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)7.69ChemAxon
pKa (Strongest Basic)5.83ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area116.47 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity146.61 m3·mol-1ChemAxon
Polarizability57.75 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Kind
Protein group
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...

Components:

Drug created on October 20, 2016 14:48 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates